Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

Agarwal, 2009, Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory, J. Immunol., 183, 1695, 10.4049/jimmunol.0900592

Brentjens, 2003, Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15, Nat. Med., 9, 279, 10.1038/nm827

Brentjens, 2007, Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts, Clinical cancer research, 13, 5426, 10.1158/1078-0432.CCR-07-0674

Brentjens, 2011, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, Blood, 118, 4817, 10.1182/blood-2011-04-348540

Carpenito, 2009, Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains, Proc. Natl. Acad. Sci. USA, 106, 3360, 10.1073/pnas.0813101106

Chen, 2013, Molecular mechanisms of T cell co-stimulation and co-inhibition, Nat. Rev. Immunol., 13, 227, 10.1038/nri3405

Chin, 1996, Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1, Science, 272, 719, 10.1126/science.272.5262.719

Condomines, 2015, Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition, PLoS ONE, 10, e0130518, 10.1371/journal.pone.0130518

Curtsinger, 2010, Inflammatory cytokines as a third signal for T cell activation, Curr. Opin. Immunol., 22, 333, 10.1016/j.coi.2010.02.013

Davila, 2012, How do CARs work?: Early insights from recent clinical studies targeting CD19, OncoImmunology, 1, 1577, 10.4161/onci.22524

Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci. Transl. Med., 6, 224ra25, 10.1126/scitranslmed.3008226

Diamond, 2011, Type I interferon is selectively required by dendritic cells for immune rejection of tumors, J. Exp. Med., 208, 1989, 10.1084/jem.20101158

Fuertes, 2011, Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells, J. Exp. Med., 208, 2005, 10.1084/jem.20101159

Gade, 2005, Targeted elimination of prostate cancer by genetically directed human T lymphocytes, Cancer Res., 65, 9080, 10.1158/0008-5472.CAN-05-0436

Gallardo, 1997, The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes, Gene Ther., 4, 1115, 10.1038/sj.gt.3300506

Golding, 2010, Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses, Immunology, 131, 107, 10.1111/j.1365-2567.2010.03280.x

Gong, 1999, Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen, Neoplasia, 1, 123, 10.1038/sj.neo.7900018

Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N. Engl. J. Med., 368, 1509, 10.1056/NEJMoa1215134

Hervas-Stubbs, 2010, Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8(+) T cells, Eur. J. Immunol., 40, 3389, 10.1002/eji.201040664

Ho, 2003, Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction, Cancer Cell, 3, 431, 10.1016/S1535-6108(03)00113-2

Honda, 2006, IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors, Nat. Rev. Immunol., 6, 644, 10.1038/nri1900

Honda, 2005, IRF-7 is the master regulator of type-I interferon-dependent immune responses, Nature, 434, 772, 10.1038/nature03464

Ikeda, 2002, The roles of IFN gamma in protection against tumor development and cancer immunoediting, Cytokine Growth Factor Rev., 13, 95, 10.1016/S1359-6101(01)00038-7

Imai, 2004, Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia, Leukemia, 18, 676, 10.1038/sj.leu.2403302

Ivashkiv, 2014, Regulation of type I interferon responses, Nat. Rev. Immunol., 14, 36, 10.1038/nri3581

Jaime-Ramirez, 2011, IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production, J. Immunol., 186, 3401, 10.4049/jimmunol.1000328

Kowolik, 2006, CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells, Cancer Res., 66, 10995, 10.1158/0008-5472.CAN-06-0160

Lee, 2011, In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy, Cancer Res., 71, 2871, 10.1158/0008-5472.CAN-10-0552

Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3

Lim, 2014, Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells, Cancer Immunol. Immunother., 63, 259, 10.1007/s00262-013-1506-7

Maher, 2002, Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor, Nat. Biotechnol., 20, 70, 10.1038/nbt0102-70

Manabe, 1993, Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. I. Cytotoxicity of interferon alpha in acute lymphoblastic leukemia, Leukemia, 7, 1990

Marshall, 2010, IFN-alpha beta and self-MHC divert CD8 T cells into a distinct differentiation pathway characterized by rapid acquisition of effector functions, J. Immunol., 185, 1419, 10.4049/jimmunol.1001140

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N. Engl. J. Med., 371, 1507, 10.1056/NEJMoa1407222

Mescher, 2006, Signals required for programming effector and memory development by CD8+ T cells, Immunol. Rev., 211, 81, 10.1111/j.0105-2896.2006.00382.x

Miller, 2015, The journey from discoveries in fundamental immunology to cancer immunotherapy, Cancer Cell, 27, 439, 10.1016/j.ccell.2015.03.007

Milone, 2009, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo, Molecular therapy, 17, 1453, 10.1038/mt.2009.83

Ngiow, 2011, Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors, Cancer Res., 71, 3540, 10.1158/0008-5472.CAN-11-0096

Nguyen, 2002, Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection, Science, 297, 2063, 10.1126/science.1074900

Nishikawa, 2005, IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response, J. Immunol., 175, 4433, 10.4049/jimmunol.175.7.4433

Park, 1999, Structural basis for self-association and receptor recognition of human TRAF2, Nature, 398, 533, 10.1038/19110

Ramos, 2014, CD19-CAR trials, Cancer J., 20, 112, 10.1097/PPO.0000000000000031

Rivière, 1995, Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells, Proc. Natl. Acad. Sci. USA, 92, 6733, 10.1073/pnas.92.15.6733

Sadelain, 2015, CAR therapy: the CD19 paradigm, J. Clin. Invest., 125, 3392, 10.1172/JCI80010

Sadelain, 2009, The promise and potential pitfalls of chimeric antigen receptors, Curr. Opin. Immunol., 21, 215, 10.1016/j.coi.2009.02.009

Saoulli, 1998, CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand, J. Exp. Med., 187, 1849, 10.1084/jem.187.11.1849

Sasai, 2010, Direct binding of TRAF2 and TRAF6 to TICAM-1/TRIF adaptor participates in activation of the Toll-like receptor 3/4 pathway, Mol. Immunol., 47, 1283, 10.1016/j.molimm.2009.12.002

Sato, 1998, Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7, FEBS Lett., 441, 106, 10.1016/S0014-5793(98)01514-2

Shin, 2006, A signal through 4-1BB ligand inhibits receptor for activation of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis by increasing interferon (IFN)-beta production, FEBS Lett., 580, 1601, 10.1016/j.febslet.2006.01.091

Spaapen, 2014, Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature, J. Immunol., 193, 4254, 10.4049/jimmunol.1401109

Srivastava, 2014, Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection, J. Exp. Med., 211, 961, 10.1084/jem.20131556

Stephan, 2007, T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection, Nat. Med., 13, 1440, 10.1038/nm1676

Stetson, 2006, Type I interferons in host defense, Immunity, 25, 373, 10.1016/j.immuni.2006.08.007

Subramanian, 2005, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. USA, 102, 15545, 10.1073/pnas.0506580102

Tammana, 2010, 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies, Hum. Gene Ther., 21, 75, 10.1089/hum.2009.122

Tsukahara, 2013, CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models, Biochem. Biophys. Res. Commun., 438, 84, 10.1016/j.bbrc.2013.07.030

van der Stegen, 2015, The pharmacology of second-generation chimeric antigen receptors, Nat. Rev. Drug Discov., 14, 499, 10.1038/nrd4597

Wigginton, 2001, IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy, J. Clin. Invest., 108, 51, 10.1172/JCI200110128

Yang, 2014, Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses, Cancer Cell, 25, 37, 10.1016/j.ccr.2013.12.004

Ysebrant de Lendonck, 2013, Interferon regulatory factor 3 controls interleukin-17 expression in CD8 T lymphocytes, Proc. Natl. Acad. Sci. USA, 110, E3189, 10.1073/pnas.1219221110

Zhao, 2009, A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity, J. Immunol., 183, 5563, 10.4049/jimmunol.0900447

Zhong, 2010, Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication, Mol. Ther., 18, 413, 10.1038/mt.2009.210